Evidence map›Paper›PMID 40083318›Full record

ArticleThe Journal of infectious diseases2025

A Miniaturized Assay to Evaluate Plasmodium cynomolgi and Plasmodium knowlesi as Models for Prioritizing Plasmodium vivax Vaccine Targets.

Sheena Dass, Prasun Kundu, Deboki Naskar, Usheer Kanjee, Marcelo U Ferreira, Julian C Rayner, Manoj T Duraisingh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sheena DassDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Prasun KunduCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Deboki NaskarCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Usheer KanjeeDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Marcelo U FerreiraDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-5293-9090
Julian C RaynerCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-9835-1014
Manoj T DuraisinghDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0001-7694-8867

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Elucidating ligand-receptor interactions required for Plasmodium vivax blood-stage infectionR01AI140751 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI DURAISINGH, MANOJ T · 2018 to 2022
$2.0M
Large Scale systematic priorization of Plasmodium vivax blood stage vaccine antigensR01AI137154 · NIAID · UNIVERSITY OF CAMBRIDGE · PI RAYNER, JULIAN CHARLES · 2018 to 2021
$1.4M
National Institutes of Health/National Institute of Allergy and Infectious Diseases 5R01AI137154National Institutes of Health/National Institute of Allergy and Infectious Diseases 5R01AI140751NIAID NIH HHS R01 AI137154NIAID NIH HHS R01 AI140751NIH HHS P51 OD011132
6 · The paper itself

Abstract

Plasmodium vivax vaccine discovery lags behind Plasmodium falciparum due to the absence of a reliable in vitro culture system. We developed a miniature 384-well assay for the evolutionarily related parasite species Plasmodium cynomolgi and Plasmodium knowlesi, deploying it for screening invasion inhibition efficacy of antibodies elicited against 8 P. vivax proteins. All 8 antibodies showed consistent inhibition across both P. knowlesi and P. cynomolgi species, correlating with inhibition in ex vivo P. vivax isolates. The use of simian malaria parasites and this assay represent a robust, high-throughput method for prioritizing P. vivax blood-stage vaccine candidates.

Indexed as

Malaria VaccinesMalaria, VivaxPlasmodium cynomolgiPlasmodium knowlesiPlasmodium vivaxAnimalsAntibodies, ProtozoanHumansAntibodies, ProtozoanMalaria Vaccinesblood-stage vaccinesinvasion inhibitionP. cynomolgiP. knowlesiP. vivax

Identifiers

PMID40083318
PMCPMC12526954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.